Keyword: Jazz Pharmaceuticals
Just over a month after walking out on troubled cancer biotech Immunomedics, Robert Iannone, M.D., has taken up the research chief job at Jazz.
Spark Therapeutics agreed to sell its priority review voucher, good for four months off an FDA review, to Jazz Pharmaceuticals for $110 million.
AZ research exec Johnson jumps to Goldfinch, Human Longevity undergoes C-suite earthquake, Biogen poaches Takeda exec as CIO.
The deal gives Jazz an option to pick up worldwide rights to two hematology antibody-drug conjugates and a third as-yet-unidentified program.
Upon its March approval, Jazz Pharma’s Defitelio became the first marketed drug to treat severe hepatic veno-occlusive disease in the U.S., providing a significant therapeutic advance to a small group of patients.
The Wall Street Journal kicked off rumors over the Memorial Day weekend that Ireland’s Jazz Pharmaceuticals was set to buy Celator, and early this morning the two confirmed the $1.5 billion deal was to go ahead.
Jazz, which markets Xyrem for narcolepsy, led a $49 million round to launch Arrivo BioVentures.
